- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eli Lilly and Company (LLY)
Eli Lilly and Company stock price live, this page displays NYSE LLY stock exchange data. View the LLY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eli Lilly and Company real time stock price chart below.
What Is the Eli Lilly and Company Stock Price Today?
The Eli Lilly and Company stock price today is 762.73.
What Is the Stock Symbol for Eli Lilly and Company?
The stock symbol for Eli Lilly and Company is ""LLY.""
What Stock Exchange Does Eli Lilly and Company Trade On?
Eli Lilly and Company is listed and trades on the NYSE stock exchange.
Is Eli Lilly and Company a Good Stock to Buy?
Determining whether Eli Lilly and Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LLY quote. (ISIN: US5324571083)
What Is the Eli Lilly and Company Stock Price Today?
The Eli Lilly and Company stock price today is 762.73.
What Is the Stock Symbol for Eli Lilly and Company?
The stock symbol for Eli Lilly and Company is ""LLY.""
What Stock Exchange Does Eli Lilly and Company Trade On?
Eli Lilly and Company is listed and trades on the NYSE stock exchange.
Is Eli Lilly and Company a Good Stock to Buy?
Determining whether Eli Lilly and Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LLY quote. (ISIN: US5324571083)
762.73
-22.30(-2.84%)
Closed·
After Hours
762.90+0.17(+0.02%)
·
Fair Value
An estimate of a Eli Lilly's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
755.56
786.00
52 wk Range
677.09
972.53
LLY Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
LLY is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Eli Lilly's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
755.56786.00
52 wk Range
677.09972.53
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.79%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.79%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LLY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Eli Lilly's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
951.98
Upside
+24.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Eli Lilly’s Alzheimer’s drug gets EMA re-examination
- Investing.com
- Eli Lilly’s Alzheimer’s drug gets EMA re-examination
- Investing.com
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company SWOT Analysis
GLP-1 Market Leade | Eli Lilly dominates the GLP-1 and obesity treatment markets with Mounjaro and Zepbound, driving significant growth despite recent challenges in Q4 2024 |
Pipeline Potential | Explore Eli Lilly's promising pipeline, including Orforglipron, an oral GLP-1 agonist in Phase 3 trials for diabetes and obesity, poised to revolutionize treatment |
Financial Outlook | Analysts project Eli Lilly's price targets between $650 and $1,190, with 2025 revenue forecasts ranging from $58 billion to $61 billion |
Market Expansion | Learn how Eli Lilly plans to capitalize on global markets and potential Medicare coverage for obesity treatments, while navigating supply constraints and competition |
Eli Lilly and Company Earnings Call Summary for Q1/2025
- Q1 revenue up 45% YoY to $12.73B, driven by key products; EPS of $3.34 missed $3.46 forecast
- Stock dropped 8.56% post-earnings; company trades above Fair Value per InvestingPro analysis
- Gross margin improved to 83.5%; non-GAAP performance margin up 11+ points to 42.6%
- Full-year revenue guidance reaffirmed; phase 3 data for orforglipron expected by end of 2025
- CEO highlighted promising Achieve One trial results, increased U.S. manufacturing investments
Last Updated: 01/05/2025, 16:18
Read Full TranscriptCompare LLY to Peers and Sector
Metrics to compare | LLY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLLYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 61.7x | 17.8x | −0.5x | |
PEG Ratio | 0.76 | 0.07 | 0.00 | |
Price/Book | 43.4x | 2.8x | 2.6x | |
Price / LTM Sales | 14.0x | 4.1x | 3.0x | |
Upside (Analyst Target) | 27.2% | 143.2% | 52.4% | |
Fair Value Upside | Unlock | 6.0% | 8.7% | Unlock |
Analyst Ratings
22 Buy
4 Hold
2 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 951.98
(+24.81% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
3.34 / 3.46
Revenue / Forecast
12.73B / 12.72B
People Also Watch
FAQ
What Stock Exchange Does Eli Lilly Trade On?
Eli Lilly is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Eli Lilly?
The stock symbol for Eli Lilly is "LLY."
What Is the Eli Lilly Market Cap?
As of today, Eli Lilly market cap is 684.73B.
What Is Eli Lilly's Earnings Per Share (TTM)?
The Eli Lilly EPS (TTM) is 12.34.
When Is the Next Eli Lilly Earnings Date?
Eli Lilly will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is LLY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Eli Lilly Stock Split?
Eli Lilly has split 5 times.
How Many Employees Does Eli Lilly Have?
Eli Lilly has 47000 employees.
What is the current trading status of Eli Lilly (LLY)?
As of 22 Jun 2025, Eli Lilly (LLY) is trading at a price of 762.73, with a previous close of 785.03. The stock has fluctuated within a day range of 755.56 to 786.00, while its 52-week range spans from 677.09 to 972.53.
What Is Eli Lilly (LLY) Price Target According to Analysts?
The average 12-month price target for Eli Lilly is USD951.97519, with a high estimate of USD1190 and a low estimate of USD650. 22 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +24.81% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.